The vascular contribution to Alzheimer's disease

Clinical Science

Volumn 119, Issue 10, 2010, Pages 407-421

  Altman, Robin ^a   Rutledge, John C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E (apoe); Astrocyte; Endothelial cell; Lipoprotein; Triacylglycerol rich lipoprotein (tgrl); Vascular system

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CHOLESTEROL; LIPID; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL;

ALLELE; ALZHEIMER DISEASE; ASTROCYTE; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; HUMAN; INFLAMMATION; LIPOLYSIS; MICROVASCULATURE; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BRAIN; DISEASE PROGRESSION; HUMANS; LIPIDS; LIPOLYSIS; LIPOPROTEINS; PROTEIN CONFORMATION; RISK FACTORS; VASCULAR DISEASES;

EID: 77956410028     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20100094     Document Type: Review

References (222)

1. Aggarwal, N. T. and Decarli, C. (2007) Vascular dementia: emerging trends. Semin. Neurol. 27, 66-77
2. Chui, H. C., Zarow, C., Mack, W. J., Ellis, W. G., Zheng, L., Jagust, W. J., Mungas, D., Reed, B. R., Kramer, J. H., Decarli, C. C. et al. (2006) Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann. Neurol. 60, 677-687
3. DeCarli, C. (2003) The role of cerebrovascular disease in dementia. Neurologist 9, 123-136
4. DeCarli, C. S. (2006) When two are worse than one: stroke and Alzheimer disease. Neurology 67, 1326-1327
5. Berglund, L., Wiklund, O., Eggertsen, G., Olofsson, S. O., Eriksson, M., Linden, T., Bondjers, G. and Angelin, B. (1993) Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy. J. Intern. Med. 233, 173-178
6. Abbott, N. J., Ronnback, L. and Hansson, E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41-53
7. Benarroch, E. E. (2007) Neurovascular unit dysfunction: a vascular component of Alzheimer disease? Neurology 68, 1730-1732
8. Gee, J. R. and Keller, J. N. (2005) Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int. J. Biochem. Cell Biol. 37, 1145-1150
9. Haseloff, R. F., Blasig, I. E., Bauer, H. C. and Bauer, H. (2005) In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell. Mol. Neurobiol. 25, 25-39
10. Parri, R. and Crunelli, V. (2003) An astrocyte bridge from synapse to blood flow. Nat. Neurosci. 6, 5-6
11. Zlokovic, B. V. (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201
12. Abramov, A. Y. and Duchen, M. R. (2005) The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid β peptides. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360, 2309-2314
13. Blasko, I., Stampfer-Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P. and Grubeck-Loebenstein, B. (2004) How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 3, 169-176 (Pubitemid 40253499)
14. Drew, P. D., Xu, J., Storer, P. D., Chavis, J. A. and Racke, M. K. (2006) Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem. Int. 49, 183-189
15. Huang, Y., Weisgraber, K. H., Mucke, L. and Mahley, R. W. (2004) Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J. Mol. Neurosci. 23, 189-204
16. Husemann, J. and Silverstein, S. C. (2001) Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. Am. J. Pathol. 158, 825-832
17. Kadiu, I., Glanzer, J. G., Kipnis, J., Gendelman, H. E. and Thomas, M. P. (2005) Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotox. Res. 8, 25-50
18. Miao, H., Hu, Y. L., Shiu, Y. T., Yuan, S., Zhao, Y., Kaunas, R., Wang, Y., Jin, G., Usami, S. and Chien, S. (2005) Effects of flow patterns on the localization and expression of VE-cadherin at vascular endothelial cell junctions: in vivo and in vitro investigations. J. Vasc. Res. 42, 77-89
19. Minagar, A., Shapshak, P., Fujimura, R., Ownby, R., Heyes, M. and Eisdorfer, C. (2002) The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 202, 13-23
20. Rossner, S. (2004) New players in old amyloid precursor protein-processing pathways. Int. J. Dev. Neurosci. 22, 467-474
21. Sastre, M., Klockgether, T. and Heneka, M. T. (2006) Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 24, 167-176
22. Strazielle, N., Ghersi-Egea, J. F., Ghiso, J., Dehouck, M. P., Frangione, B., Patlak, C., Fenstermacher, J. and Gorevic, P. (2000) In vitro evidence that β-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J. Neuropathol. Exp. Neurol. 59, 29-38
23. Bowman, G. L., Kaye, J. A., Moore, M., Waichunas, D., Carlson, N. E. and Quinn, J. F. (2007) Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68, 1809-1814
24. Bell, R. D. and Zlokovic, B. V. (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103-113
25. Desai, T. R., Leeper, N. J., Hynes, K. L. and Gewertz, B. L. (2002) Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J. Surg. Res. 104, 118-123
26. Lashuel, H. A. (2005) Membrane permeabilization: a common mechanism in protein-misfolding diseases. Sci. Aging Knowl. Environ. 2005, pe28
27. Persidsky, Y., Ramirez, S., Haorah, J. and Kanmogne, G. (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1, 223-236
28. Simionescu, M. and Antohe, F. (2006) Functional ultrastructure of the vascular endothelium: changes in various pathologies. Handb. Exp. Pharmacol. 176, 41-69
29. Saido, T. C. and Iwata, N. (2006) Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease: towards presymptomatic diagnosis, prevention and therapy. Neurosci. Res. 54, 235-253
30. Skovronsky, D. M., Lee, V. M. and Pratico, D. (2001) Amyloid precursor protein and amyloid β peptide in human platelets. Role of cyclooxygenase and protein kinase C. J. Biol. Chem. 276, 17036-17043
31. Mayeux, R., Tang, M. X., Jacobs, D. M., Manly, J., Bell, K., Merchant, C., Small, S. A., Stern, Y., Wisniewski, H. M. and Mehta, P. D. (1999) Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46, 412-416
32. Mayeux, R. M., Honig, L. S. M., Tang, M. X. P., Manly, J. P., Stern, Y. P., Schupf, N. P. and Mehta, P. D. P. (2003) Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185-1190
33. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W. et al. (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870
34. Ellis, R. J., Olichney, J. M., Thal, L. J., Mirra, S. S., Morris, J. C., Beekly, D. and Heyman, A. (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46, 1592-1596 (Pubitemid 26185777)
35. Attems, J., Quass, M., Jellinger, K. A. and Lintner, F. (2007) Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J. Neurol. Sci. 257, 49-55
36. Attems, J., Jellinger, K. A. and Lintner, F. (2005) Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol. 110, 222-231
37. Pfeifer, L. A. M., White, L. R. M., Ross, G. W. M., Petrovitch, H. M. and Launer, L. J. P. (2002) Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 58, 1629-1634
38. Herzig, M. C., Van Nostrand, W. E. and Jucker, M. (2006) Mechanism of cerebral β-amyloid angiopathy: murine and cellular models. Brain Pathol. 16, 40-54
39. Vinters, H. V., Secor, D. L., Read, S. L., Frazee, J. G., Tomiyasu, U., Stanley, T. M., Ferreiro, J. A. and Akers, M. A. (1994) Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. Ultrastruct. Pathol. 18, 333-348
40. Mok, S. S., Losic, D., Barrow, C. J., Turner, B. J., Masters, C. L., Martin, L. L. and Small, D. H. (2006) The β-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane. J. Neurochem. 96, 53-64
41. Christie, R., Yamada, M., Moskowitz, M. and Hyman, B. (2001) Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol. 158, 1065-1071
42. Paris, D., Ait-Ghezala, G., Mathura, V. S., Patel, N., Quadros, A., Laporte, V. and Mullan, M. (2005) Anti-angiogenic activity of the mutant Dutch Aβ peptide on human brain microvascular endothelial cells. Brain Res. Mol. Brain Res. 136, 212-230
43. Paris, D., Humphrey, J., Quadros, A., Patel, N., Crescentini, R., Crawford, F. and Mullan, M. (2003) Vasoactive effects of Aβ in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol. Res. 25, 642-651
44. Paris, D., Townsend, K., Quadros, A., Humphrey, J., Sun, J., Brem, S., Wotoczek-Obadia, M., DelleDonne, A., Patel, N., Obregon, D. F. et al. (2004) Inhibition of angiogenesis by Aβ peptides. Angiogenesis 7, 75-85
45. Stopa, E. G. M. D., Butala, P. M. D., Salloway, S. M. D., Johanson, C. E. P., Gonzalez, L. P., Tavares, R. B., Hovanesian, V. B., Hulette, C. M. M. D., Vitek, M. P. P. and Cohen, R. A. P. (2008) Cerebral cortical arteriolar angiopathy, vascular β-amyloid, smooth muscle actin, braak stage, and ApoE genotype. Stroke 39, 814-821
46. Thal, D. R., Capetillo-Zarate, E., Larionov, S., Staufenbiel, M., Zurbruegg, S. and Beckmann, N. (2009) Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol. Aging 30, 1936-1948
47. Fazio, S., Linton, M. F. and Swift, L. L. (2000) The cell biology and physiologic relevance of ApoE recycling. Trends Cardiovasc. Med. 10, 23-30
48. Lahiri, D. K. (2004) Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. J. Mol. Neurosci. 23, 225-233
49. Miserez, A. R., Scharnagl, H., Muller, P. Y., Mirsaidi, R., Stahelin, H. B., Monsch, A., Marz, W. and Hoffmann, M. M. (2003) Apolipoprotein E3Basel: new insights into a highly conserved protein region. Eur. J. Clin. Invest. 33, 677-685
50. Karlsson, H., Leanderson, P., Tagesson, C. and Lindahl, M. (2005) Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5, 551-565 (Pubitemid 40262072)
51. Mahley, R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630
52. Anuurad, E., Rubin, J., Lu, G., Pearson, T. A., Holleran, S., Ramakrishnan, R. and Berglund, L. (2006) Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J. Lipid Res. 47, 2475-2481
53. Berglund, L. (2001) The APOE gene and diets-food (and drink) for thought. Am. J. Clin. Nutr. 73, 669-670
54. Eggertsen, G., Heimburger, O., Stenvinkel, P. and Berglund, L. (1997) Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. Nephrol. Dial. Transplant. 12, 141-144
55. Eggertsen, G., Tegelman, R., Ericsson, S., Angelin, B. and Berglund, L. (1993) Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clin. Chem. 39, 2125-2129
56. Hyson, D., Rutledge, J. C. and Berglund, L. (2003) Postprandial lipemia and cardiovascular disease. Curr. Atheroscler. Rep. 5, 437-444
57. Isasi, C. R., Shea, S., Deckelbaum, R. J., Couch, S. C., Starc, T. J., Otvos, J. D. and Berglund, L. (2000) Apolipoprotein ε2 allele is associated with an anti-atherogenic lipoprotein profile in children: the Columbia University BioMarkers Study. Pediatrics 106, 568-575
58. Pablos-Mendez, A., Mayeux, R., Ngai, C., Shea, S. and Berglund, L. (1997) Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioscler. Thromb. Vasc. Biol. 17, 3534-3541
59. Romas, S. N., Tang, M. X., Berglund, L. and Mayeux, R. (1999) APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53, 517-521 (Pubitemid 29382044)
60. Rubin, J. and Berglund, L. (2002) Apolipoprotein E and diets: a case of gene-nutrient interaction? Curr. Opin. Lipidol. 13, 25-32
61. Wetterau, J. R., Aggerbeck, L. P., Rall, Jr, S. C. and Weisgraber, K. H. (1988) Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263, 6240-6248
62. Wilson, C., Wardell, M. R., Weisgraber, K. H., Mahley, R. W. and Agard, D. A. (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252, 1817-1822
63. Weisgraber, K. H., Rall, Jr, S. C. and Mahley, R. W. (1981) Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 256, 9077-9083
64. Vance, J. E., Karten, B. and Hayashi, H. (2006) Lipid dynamics in neurons. Biochem. Soc. Trans. 34, 399-403
65. Dong, L. M. and Weisgraber, K. H. (1996) Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271, 19053-19057
66. Saito, H., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., Phillips, M. C. and Lund-Katz, S. (2003) Effects of polymorphism on the lipid interaction of human apolipoprotein E. J. Biol. Chem. 278, 40723-40729
67. Dallongeville, J., Davignon, J. and Lussier-Cacan, S. (1992) ACAT activity in freshly isolated human mononuclear cell homogenates from hyperlipidemic subjects. Metab. Clin. Exp. 41, 154-159
68. Fleisher, A., Grundman, M., Jack, Jr, C. R., Petersen, R. C., Taylor, C., Kim, H. T., Schiller, D. H., Bagwell, V., Sencakova, D., Weiner, M. F. et al. (2005) Sex, apolipoprotein Eε 4 status, and hippocampal volume in mild cognitive impairment. Arch. Neurol. 62, 953-957
69. Tiret, L., de Knijff, P., Menzel, H. J., Ehnholm, C., Nicaud, V. and Havekes, L. M. (1994) ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. European Atherosclerosis Research Study. Arterioscler. Thromb. 14, 1617-1624
70. Davignon, J., Gregg, R. E. and Sing, C. F. (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8, 1-21
71. Roses, A. D., Einstein, G., Gilbert, J., Goedert, M., Han, S. H., Huang, D., Hulette, C., Masliah, E., Pericak-Vance, M. A., Saunders, A. M. et al. (1996) Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Ann. N.Y. Acad. Sci. 777, 146-157
72. Weisgraber, K. H. and Mahley, R. W. (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10, 1485-1494
73. Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V. and Stopa, E. G. (2007) Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol. Aging 28, 977-986
74. Mahley, R. W., Weisgraber, K. H. and Huang, Y. (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 103, 5644-5651
75. Ophir, G., Amariglio, N., Jacob-Hirsch, J., Elkon, R., Rechavi, G. and Michaelson, D. M. (2005) Apolipoprotein E4 enhances brain inflammation by modulation of the NF-κB signaling cascade. Neurobiol. Dis. 20, 709-718
76. Manelli, A. M., Stine, W. B., Van Eldik, L. J. and LaDu, M. J. (2004) ApoE and Aβ1-Abet42 interactions: effects of isoform and conformation on structure and function. J. Mol. Neurosci. 23, 235-246
77. Mullick, A. E., Powers, A. F., Kota, R. S., Tetali, S. D., Eiserich, J. P. and Rutledge, J. C. (2007) Apolipoprotein E3- and nitric oxide-dependent modulation of endothelial cell inflammatory responses. Arterioscler. Thromb. Vasc. Biol. 27, 339-345
78. Ophir, G., Meilin, S., Efrati, M., Chapman, J., Karussis, D., Roses, A. and Michaelson, D. M. (2003) Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice. Neurobiol. Dis. 12, 56-64
79. Rubinsztein, D. C., Hanlon, C. S., Irving, R. M., Goodburn, S., Evans, D. G., Kellar-Wood, H., Xuereb, J. H., Bandmann, O. and Harding, A. E. (1994) Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Mol. Cell. Probes 8, 519-525
80. Barger, S. W. and Harmon, A. D. (1997) Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881
81. Reference deleted
82. Tetali, S. D., Budamagunta, M. S., Voss, J. C. and Rutledge, J. C. (2006) C-terminal interactions of apolipoprotein E4 respond to the postprandial state. J. Lipid Res. 47, 1358-1365
83. Bradley, W. A. and Gianturco, S. H. (1986) ApoE is necessary and sufficient for the binding of large triglyceride-rich lipoproteins to the LDL receptor; apoB is unnecessary. J. Lipid Res. 27, 40-48
84. Brown, S. A., Via, D. P., Gotto, Jr, A. M., Bradley, W. A. and Gianturco, S. H. (1986) Apolipoprotein E-mediated binding of hypertriglyceridemic very low density lipoproteins to isolated low density lipoprotein receptors detected by ligand blotting. Biochem. Biophys. Res. Commun. 139, 333-340
85. Gianturco, S. H. and Bradley, W. A. (1986) Interactions of triglyceride-rich lipoproteins with receptors: modulation by thrombin. Semin. Thromb. Hemostasis 12, 277-279
86. Gianturco, S. H., Gotto, Jr, A. M., Hwang, S. L., Karlin, J. B., Lin, A. H., Prasad, S. C. and Bradley, W. A. (1983) Apolipoprotein E mediates uptake of Sf 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J. Biol. Chem. 258, 4526-4533
87. Hatters, D. M., Budamagunta, M. S., Voss, J. C. and Weisgraber, K. H. (2005) Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms. J. Biol. Chem. 280, 34288-34295
88. Wolozin, B., Manger, J., Bryant, R., Cordy, J., Green, R. C. and McKee, A. (2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol. Scand. Suppl. 185, 63-70
89. Abildayeva, K., Jansen, P. J., Hirsch-Reinshagen, V., Bloks, V. W., Bakker, A. H., Ramaekers, F. C., de Vente, J., Groen, A. K., Wellington, C. L., Kuipers, F. and Mulder, M. (2006) 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281, 12799-12808
90. Burgess, B. L., Parkinson, P. F., Racke, M. M., Hirsch-Reinshagen, V., Fan, J., Wong, C., Stukas, S., Theroux, L., Chan, J. Y., Donkin, J. et al. (2008) ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 49, 1254-1267
91. Fan, J., Donkin, J. and Wellington, C. (2009) Greasing the wheels of Aβ clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. Biofactors 35, 239-248
92. Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L. et al. (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 58, 681-693
93. Kim, W. S., Chan, S. L., Hill, A. F., Guillemin, G. J. and Garner, B. (2009) Impact of 27-hydroxycholesterol on amyloid-β peptide production and ATP-binding cassette transporter expression in primary human neurons. J Alzheimers Dis. 16, 121-131
94. Vaya, J. and Schipper, H. M. (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J. Neurochem. 102, 1727-1737
95. Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R. and Zlokovic, B. V. (2007) Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27, 909-918
96. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M. and Zlokovic, B. V. (2008) apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013
97. Hirsch-Reinshagen, V., Chan, J. Y., Wilkinson, A., Tanaka, T., Fan, J., Ou, G., Maia, L. F., Singaraja, R. R., Hayden, M. R. and Wellington, C. L. (2007) Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-β peptide levels in vivo. J. Lipid Res. 48, 914-923
98. Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R. et al. (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118, 671-682
99. Eckert, G. P., Vardanian, L., Rebeck, G. W. and Burns, M. P. (2007) Regulation of central nervous system cholesterol homeostasis by the liver X receptor agonist TO-901317. Neurosci. Lett. 423, 47-52
100. Lefterov, I., Bookout, A., Wang, Z., Staufenbiel, M., Mangelsdorf, D. and Koldamova, R. (2007) Expression profiling in APP23 mouse brain: inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment. Mol. Neurodegener. 2, 20
101. Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J. et al. (2007) The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34, 621-628
102. Mahley, R. W., Huang, Y. and Weisgraber, K. H. (2006) Putting cholesterol in its place: apoE and reverse cholesterol transport. J. Clin. Invest. 116, 1226-1229
103. Gofman, J. W. (1950) Blood lipoproteins and atherosclerosis. J. Clin. Invest. 29, 815-816
104. Gofman, J. W., Jones, H. B., Lindgren, F. T., Lyon, T. P., Elliott, H. A. and Strisower, B. (1950) Blood lipids and human atherosclerosis. Circulation 2, 161-178
105. Gofman, J. W. and Lindgren, F. (1950) The role of lipids and lipoproteins in atherosclerosis. Science 111, 166-171
106. Rader, D. J., Cohen, J. and Hobbs, H. H. (2003) Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111, 1795-1803
107. Goldberg, I. J., Kako, Y. and Lutz, E. P. (2000) Responses to eating: lipoproteins, lipolytic products and atherosclerosis. Curr. Opin. Lipidol. 11, 235-241
108. Goldberg, I. J. and Merkel, M. (2001) Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front. Biosci. 6, D388-D405
109. Lopez-Miranda, J., Perez-Martinez, P., Marin, C., Moreno, J. A., Gomez, P. and Perez-Jimenez, F. (2006) Postprandial lipoprotein metabolism, genes and risk of cardiovascular disease. Curr. Opin. Lipidol. 17, 132-138
110. Merkel, M., Eckel, R. H. and Goldberg, I. J. (2002) Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43, 1997-2006
111. Otarod, J. K. and Goldberg, I. J. (2004) Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr. Atheroscler. Rep. 6, 335-342
112. de la Torre, J. C. (2006) How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol. Res. 28, 637-644
113. Decarli, C. (2004) Vascular factors in dementia: an overview. J. Neurol. Sci. 226, 19-23
114. Mielke, M. M. and Lyketsos, C. G. (2006) Lipids and the pathogenesis of Alzheimer's disease: is there a link? Int. Rev. Psychiatry 18, 173-186
115. Panza, F., D'Introno, A., Colacicco, A. M., Capurso, C., Pichichero, G., Capurso, S. A., Capurso, A. and Solfrizzi, V. (2006) Lipid metabolism in cognitive decline and dementia. Brain Res. Brain Res. Rev. 51, 275-292
116. Sjogren, M., Mielke, M., Gustafson, D., Zandi, P. and Skoog, I. (2006) Cholesterol and Alzheimer's disease-is there a relation? Mech. Ageing Dev. 127, 138-147
117. Skoog, I. and Gustafson, D. (2006) Update on hypertension and Alzheimer's disease. Neurol. Res. 28, 605-611
118. Wolozin, B. and Bednar, M. M. (2006) Interventions for heart disease and their effects on Alzheimer's disease. Neurol. Res. 28, 630-636
119. Hartmann, T., Kuchenbecker, J. and Grimm, M. O. (2007) Alzheimer's disease: the lipid connection. J. Neurochem. 103 (Suppl. 1), 159-170
120. Hirsch-Reinshagen, V., Burgess, B. L. and Wellington, C. L. (2009) Why lipids are important for Alzheimer disease? Mol. Cell. Biochem. 326, 121-129
121. Kivipelto, M. and Solomon, A. (2006) Cholesterol as a risk factor for Alzheimer's disease: epidemiological evidence. Acta Neurol. Scand. Suppl. 185, 50-57
122. Lesser, G. T., Haroutunian, V., Purohit, D. P., Schnaider Beeri, M., Schmeidler, J., Honkanen, L., Neufeld, R. and Libow, L. S. (2009) Serum lipids are related to Alzheimer's pathology in nursing home residents. Dement. Geriatr. Cogn. Disord. 27, 42-49
123. Liu, J. P., Tang, Y., Zhou, S., Toh, B. H., McLean, C. and Li, H. (2010) Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol. Cell. Neurosci. 43, 33-42
124. Panza, F., Capurso, C., D'Introno, A., Colacicco, A. M., Vasquez, F., Pistoia, G., Capurso, A. and Solfrizzi, V. (2006) Serum total cholesterol as a biomarker for Alzheimer's disease: mid-life or late-life determinations? Exp. Gerontol. 41, 805-806
125. Kandiah, N. and Feldman, H. H. (2009) Therapeutic potential of statins in Alzheimer's disease. J. Neurol. Sci. 283, 230-234
126. Purandare, N. (2009) Preventing dementia: role of vascular risk factors and cerebral emboli. Br. Med. Bull. 91, 49-59
127. Solomon, A. and Kivipelto, M. (2009) Cholesterol-modifying strategies for Alzheimer's disease. Expert Rev. Neurotherapeutics 9, 695-709
128. Cankurtaran, M., Yavuz, B. B., Halil, M., Dagli, N., Cankurtaran, E. S. and Ariogul, S. (2005) Are serum lipid and lipoprotein levels related to dementia? Arch. Gerontol. Geriatr. 41, 31-39
129. Raffaitin, C., Gin, H., Empana, J. P., Helmer, C., Berr, C., Tzourio, C., Portet, F., Dartigues, J. F., Alperovitch, A. and Barberger-Gateau, P. (2009) Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32, 169-174
130. Sabbagh, M., Zahiri, H. R., Ceimo, J., Cooper, K., Gaul, W., Connor, D. and Sparks, D. L. (2004) Is there a characteristic lipid profile in Alzheimer's disease? J. Alzheimers Dis. 6, 585-589
131. Razay, G., Vreugdenhil, A. and Wilcock, G. (2007) The metabolic syndrome and Alzheimer disease. Arch. Neurol. 64, 93-96
132. Nguyen, H. N., Son, D. J., Lee, J. W., Hwang, D. Y., Kim, Y. K., Cho, J. S., Lee, U. S., Yoo, H. S., Moon, D. C., Oh, K. W. and Hong, J. T. (2006) Mutant presenilin 2 causes abnormality in the brain lipid profile in the development of Alzheimer's disease. Arch. Pharm. Res. 29, 884-889
133. Burgess, B. L., McIsaac, S. A., Naus, K. E., Chan, J. Y., Tansley, G. H., Yang, J., Miao, F., Ross, C. J., van Eck, M., Hayden, M. R. et al. (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant Aβ in plasma. Neurobiol. Dis. 24, 114-127
134. Liu, Y., Yang, L., Conde-Knape, K., Beher, D., Shearman, M. S. and Shachter, N. S. (2004) Fatty acids increase presenilin-1 levels and γ-secretase activity in PSwt-1 cells. J. Lipid Res. 45, 2368-2376 (Pubitemid 39602985)
135. Patil, S. and Chan, C. (2005) Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci. Lett. 384, 288-293
136. Panza, F., Capurso, C., D'Introno, A., Colacicco, A. M., Del Parigi, A., Seripa, D., Pilotto, A., Capurso, A. and Solfrizzi, V. (2006) Diet, cholesterol metabolism, and Alzheimer's disease: apolipoprotein E as a possible link? J. Am. Geriatr. Soc. 54, 1963-1965
137. Phivilay, A., Julien, C., Tremblay, C., Berthiaume, L., Julien, P., Giguere, Y. and Calon, F. (2009) High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-β and tau pathologies in the 3xTg-AD model of Alzheimer's disease. Neuroscience 159, 296-307
138. Florent-Bechard, S., Desbene, C., Garcia, P., Allouche, A., Youssef, I., Escanye, M. C., Koziel, V., Hanse, M., Malaplate-Armand, C., Stenger, C. et al. (2009) The essential role of lipids in Alzheimer's disease. Biochimie 91, 804-809
139. Fotuhi, M., Mohassel, P. and Yaffe, K. (2009) Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat. Clin. Pract. Neurol. 5, 140-152
140. Hooijmans, C. R. and Kiliaan, A. J. (2008) Fatty acids, lipid metabolism and Alzheimer pathology. Eur. J. Pharmacol. 585, 176-196
141. Pauwels, E. K., Volterrani, D., Mariani, G. and Kairemo, K. (2009) Fatty acid facts, Part IV: docosahexaenoic acid and Alzheimer's disease. A story of mice, men and fish. Drug 22, 205-213
142. Boudrault, C., Bazinet, R. P. and Ma, D. W. (2009) Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. J. Nutr. Biochem. 20, 1-10
143. Das, U. N. (2008) Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease: but how and why? Prostaglandins Leukotrienes Essent. Fatty Acids 78, 11-19
144. Wang, L., Gill, R., Pedersen, T. L., Higgins, L. J., Newman, J. W. and Rutledge, J. C. (2009) Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid Res. 50, 204-213
145. Katz, R., Hamilton, J. A., Pownall, H. J., Deckelbaum, R. J., Hillard, C. J., Leboeuf, R. C. and Watkins, P. A. (2007) Brain uptake and utilization of fatty acids, lipids and lipoproteins: recommendations for future research. J. Mol. Neurosci. 33, 146-150
146. Bourre, J. M. (2006) Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 2: macronutrients. J. Nutr. Health Aging 10, 386-399
147. Chahoud, G., Aude, Y. W. and Mehta, J. L. (2004) Dietary recommendations in the prevention and treatment of coronary heart disease: do we have the ideal diet yet? Am. J. Cardiol. 94, 1260-1267
148. Heininger, K. (2000) A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum. Psychopharmacol. 15, 1-70
149. Kawas, C. H. (2006) Diet and the risk for Alzheimer's disease. Ann. Neurol. 59, 877-879
150. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N. and Schneider, J. (2003) Consumption of fish and n - 3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 60, 940-946
151. Panza, F., Capurso, C. and Solfrizzi, V. (2006) Cardiovascular factors and cognitive impairment: a role for unsaturated fatty acids and Mediterranean diet? Am. J. Cardiol. 98, 1120-1121
152. Scarmeas, N., Stern, Y., Tang, M. X., Mayeux, R. and Luchsinger, J. A. (2006) Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 59, 912-921
153. Serra-Majem, L., Roman, B. and Estruch, R. (2006) Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr. Rev. 64, S27-S47
154. Solfrizzi, V., Capurso, C. and Panza, F. (2006) Adherence to a Mediterranean dietary pattern and risk of Alzheimer's disease. Ann. Neurol. 60, 620
155. Staehelin, H. B. (2005) Micronutrients and Alzheimer's disease. Proc. Nutr. Soc. 64, 565-570
156. Weisburger, J. H. (2002) Lifestyle, health and disease prevention: the underlying mechanisms. Eur. J. Cancer Prev. 11 (Suppl. 2), S1-S7
157. Willett, W. C. (2006) The Mediterranean diet: science and practice. Public Health Nutr. 9, 105-110
158. Anekonda, T. S. (2006) Resveratrol-a boon for treating Alzheimer's disease? Brain Res. Brain Res. Rev. 52, 316-326
159. Panza, F., Capurso, C., D'Introno, A., Colacicco, A. M., Parigi, A. D., Gagliardi, G., Breglia, G., Capurso, A. and Solfrizzi, V. (2007) Mediterranean diet, mild cognitive impairment, and Alzheimer's disease. Exp. Gerontol. 42, 6-7
160. Panza, F., Solfrizzi, V., Colacicco, A. M., D'Introno, A., Capurso, C., Torres, F., Del Parigi, A., Capurso, S. and Capurso, A. (2004) Mediterranean diet and cognitive decline. Public Health Nutr. 7, 959-963
161. Petot, G. J. and Friedland, R. P. (2004) Lipids, diet and Alzheimer disease: an extended summary. J. Neurol. Sci. 226, 31-33
162. Solfrizzi, V., Panza, F. and Capurso, A. (2003) The role of diet in cognitive decline. J. Neural Transm. 110, 95-110
163. Steele, M., Stuchbury, G. and Munch, G. (2007) The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp. Gerontol. 42, 28-36
164. Veurink, G., Fuller, S. J., Atwood, C. S. and Martins, R. N. (2003) Genetics, lifestyle and the roles of amyloid β and oxidative stress in Alzheimer's disease. Ann. Hum. Biol. 30, 639-667
165. Schaefer, E. J., Bongard, V., Beiser, A. S., Lamon-Fava, S., Robins, S. J., Au, R., Tucker, K. L., Kyle, D. J., Wilson, P. W. and Wolf, P. A. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the framingham heart study. Arch. Neurol. 63, 1545-1550
166. Eiselein, L., Wilson, D. W., Lame, M. W. and Rutledge, J. C. (2007) Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am. J. Physiol. Heart Circ. Physiol. 292, H2745-H2753
167. Rutledge, J. C., Mullick, A. E., Gardner, G. and Goldberg, I. J. (2000) Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ. Res. 86, 768-773
168. Rutledge, J. C., Woo, M. M., Rezai, A. A., Curtiss, L. K. and Goldberg, I. J. (1997) Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. Circ. Res. 80, 819-828
169. Saraswathi, V. and Hasty, A. H. (2006) The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages. J. Lipid Res. 47, 1406-1415
170. Ferrante, A., Robinson, B. S., Singh, H., Jersmann, H. P., Ferrante, J. V., Huang, Z. H., Trout, N. A., Pitt, M. J., Rathjen, D. A., Easton, C. J. et al. (2006) A novel β-oxa polyunsaturated fatty acid downregulates the activation of the IκB kinase/nuclear factor κb pathway, inhibits expression of endothelial cell adhesion molecules, and depresses inflammation. Circ. Res. 99, 34-41
171. Norata, G. D., Grigore, L., Raselli, S., Redaelli, L., Hamsten, A., Maggi, F., Eriksson, P. and Catapano, A. L. (2007) Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 193, 321-327
172. Norata, G. D., Grigore, L., Raselli, S., Seccomandi, P. M., Hamsten, A., Maggi, F. M., Eriksson, P. and Catapano, A. L. (2006) Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: molecular mechanisms and gene expression studies. J. Mol. Cell. Cardiol. 40, 484-494
173. Norata, G. D., Marchesi, P., Passamonti, S., Pirillo, A., Violi, F. and Catapano, A. L. (2007) Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 191, 265-271
174. Ziouzenkova, O., Asatryan, L., Sahady, D., Orasanu, G., Perrey, S., Cutak, B., Hassell, T., Akiyama, T. E., Berger, J. P., Sevanian, A. and Plutzky, J. (2003) Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J. Biol. Chem. 278, 39874-39881
175. Ziouzenkova, O., Perrey, S., Asatryan, L., Hwang, J., MacNaul, K. L., Moller, D. E., Rader, D. J., Sevanian, A., Zechner, R., Hoefler, G. and Plutzky, J. (2003) Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc. Natl. Acad. Sci. U.S.A. 100, 2730-2735
176. Lee, J. and Goldberg, I. J. (2007) Lipoprotein lipase-derived fatty acids: physiology and dysfunction. Curr. Hypertens. Rep. 9, 462-466
177. Takahashi, M., Hiyama, Y., Yokoyama, M., Yu, S., Hu, Y., Melford, K., Bensadoun, A. and Goldberg, I. J. (2008) In vivo arterial lipoprotein lipase expression augments inflammatory responses and impairs vascular dilatation. Arterioscler. Thromb. Vasc. Biol. 28, 455-462
178. Esenabhalu, V. E., Cerimagic, M., Malli, R., Osibow, K., Levak-Frank, S., Frieden, M., Sattler, W., Kostner, G. M., Zechner, R. and Graier, W. F. (2002) Tissue-specific expression of human lipoprotein lipase in the vascular system affects vascular reactivity in transgenic mice. Br. J. Pharmacol. 135, 143-154
179. Borradaile, N. M., Han, X., Harp, J. D., Gale, S. E., Ory, D. S. and Schaffer, J. E. (2006) Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J. Lipid Res. 47, 2726-2737
180. Cnop, M., Ladriere, L., Hekerman, P., Ortis, F., Cardozo, A. K., Dogusan, Z., Flamez, D., Boyce, M., Yuan, J. and Eizirik, D. L. (2007) Selective inhibition of eukaryotic translation initiation factor 2α dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic β-cell dysfunction and apoptosis. J. Biol. Chem. 282, 3989-3997
181. Wei, Y., Wang, D. and Pagliassotti, M. J. (2007) Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells. Mol. Cell. Biochem. 303, 105-113
182. Wei, Y., Wang, D., Topczewski, F. and Pagliassotti, M. J. (2006) Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am. J. Physiol. Endocrinol. Metab. 291, E275-E281
183. Borradaile, N. M., Buhman, K. K., Listenberger, L. L., Magee, C. J., Morimoto, E. T., Ory, D. S. and Schaffer, J. E. (2006) A critical role for eukaryotic elongation factor 1A-1 in lipotoxic cell death. Mol. Biol. Cell 17, 770-778
184. Wang, H., Kouri, G. and Wollheim, C. B. (2005) ER stress and SREBP-1 activation are implicated in β-cell glucolipotoxicity. J. Cell Sci. 118, 3905-3915
185. Hoeks, J., Hesselink, M. K. and Schrauwen, P. (2006) Involvement of UCP3 in mild uncoupling and lipotoxicity. Exp. Gerontol. 41, 658-662
186. Lionetti, L., Mollica, M. P., Crescenzo, R., D'Andrea, E., Ferraro, M., Bianco, F., Liverini, G. and Iossa, S. (2007) Skeletal muscle subsarcolemmal mitochondrial dysfunction in high-fat fed rats exhibiting impaired glucose homeostasis. Int. J. Obes. 31, 1596-1604
187. Schrauwen, P. (2007) High-fat diet, muscular lipotoxicity and insulin resistance. Proc. Nutr. Soc. 66, 33-41
188. Summers, S. A. (2006) Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45, 42-72
189. Feldstein, A. E., Werneburg, N. W., Canbay, A., Guicciardi, M. E., Bronk, S. F., Rydzewski, R., Burgart, L. J. and Gores, G. J. (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology 40, 185-194
190. Feldstein, A. E., Werneburg, N. W., Li, Z., Bronk, S. F. and Gores, G. J. (2006) Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1339-G1346
191. Emerit, J., Edeas, M. and Bricaire, F. (2004) Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58, 39-46
192. Floyd, R. A. (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222, 236-245
193. Picklo, Sr, M. J. and Montine, T. J. (2007) Mitochondrial effects of lipid-derived neurotoxins. J. Alzheimers Dis. 12, 185-193
194. Laskowitz, D. T., Fillit, H., Yeung, N., Toku, K. and Vitek, M. P. (2006) Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease. Acta Neurol. Scand. Suppl. 185, 15-20
195. Patil, S., Sheng, L., Masserang, A. and Chan, C. (2006) Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci. Lett. 406, 55-59
196. Calabrese, V., Guagliano, E., Sapienza, M., Panebianco, M., Calafato, S., Puleo, E., Pennisi, G., Mancuso, C., Butterfield, D. A. and Stella, A. G. (2007) Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem. Res. 32, 757-773
197. Kim, H. S., Kong, K. A., Chung, H., Park, S. and Kim, M. H. (2007) ER stress induces the expression of Jpk, which inhibits cell cycle progression in F9 teratocarcinoma cell. Ann. N.Y. Acad. Sci. 1095, 76-81
198. Schippling, S., Kontush, A., Arlt, S., Buhmann, C., Sturenburg, H. J., Mann, U., Muller-Thomsen, T. and Beisiegel, U. (2000) Increased lipoprotein oxidation in Alzheimer's disease. Free Radical Biol. Med. 28, 351-360
199. Wang, J. Y., Wen, L. L., Huang, Y. N., Chen, Y. T. and Ku, M. C. (2006) Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr. Pharmaceut. Design 12, 3521-3533
200. Hong, H., Zeng, J. S., Kreulen, D. L., Kaufman, D. I. and Chen, A. F. (2006) Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am. J. Physiol. Heart Circ. Physiol. 291, H2210-H2215
201. 2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech. Ageing Dev. 126, 1241-1254
202. Ouyang, Y. B. and Giffard, R. G. (2004) Changes in astrocyte mitochondrial function with stress: effects of Bcl-2 family proteins. Neurochem. Int. 45, 371-379
203. Wang, L., Sapuri-Butti, A. R., Aung, H. H., Parikh, A. N. and Rutledge, J. C. (2008) Triglyceride-rich lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and produces reactive oxygen species. Am. J. Physiol. Heart Circ. Physiol. 295, H237-H244
204. Jin, J. J., Kim, H. D., Maxwell, J. A., Li, L. and Fukuchi, K. (2008) Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 5, 23
205. van Noort, J. M. and Bsibsi, M. (2009) Toll-like receptors in the CNS: implications for neurodegeneration and repair. Progr. Brain Res. 175, 139-148
206. Wong, S. W., Kwon, M. J., Choi, A. M., Kim, H. P., Nakahira, K. and Hwang, D. H. (2009) Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J. Biol. Chem. 284, 27384-27392
207. Adibhatla, R. M. and Hatcher, J. F. (2008) Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 49, 241-268
208. Bazan, N. G. (2007) Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care 10, 136-141
209. Bieschke, J., Zhang, Q., Bosco, D. A., Lerner, R. A., Powers, E. T., Wentworth, Jr, P. and Kelly, J. W. (2006) Small molecule oxidation products trigger disease-associated protein misfolding. Accounts Chem. Res. 39, 611-619
210. Farooqui, A. A., Horrocks, L. A. and Farooqui, T. (2007) Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide. J. Neurosci. Res. 85, 1834-1850
211. Farooqui, A. A., Ong, W. Y., Horrocks, L. A., Chen, P. and Farooqui, T. (2007) Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res. Rev. 56, 443-471
212. Jaeger, S. and Pietrzik, C. U. (2008) Functional role of lipoprotein receptors in Alzheimer's disease. Curr. Alzheimer Res. 5, 15-25
213. Kapoor, M., Shaw, O. and Appleton, I. (2005) Possible anti-inflammatory role of COX-2-derived prostaglandins: implications for inflammation research. Curr. Opin. Investig. Drugs. 6, 461-466
214. Leitinger, N. (2008) The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell. Biochem. 49, 325-350
215. Lukiw, W. J. and Bazan, N. G. (2008) Docosahexaenoic acid and the aging brain. J. Nutr. 138, 2510-2514
216. Mocchetti, I. and Brown, M. (2008) Targeting neurotrophin receptors in the central nervous system. CNS Neurol. Disorders Drug Targets 7, 71-82 (Pubitemid 351516218)
217. Mukherjee, P. K., Chawla, A., Loayza, M. S. and Bazan, N. G. (2007) Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukotrienes Essent. Fatty Acids 77, 233-238
218. Pomponi, M., Bria, P. and Pomponi, M. (2008) Is Alzheimer's disease a synaptic disorder? J. Alzheimers Dis. 13, 39-47
219. 2-isoprostanes as biomarkers of late-onset Alzheimer's disease. J. Mol. Neurosci. 33, 114-119
220. Farooqui, A. A. (2009) Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist 15, 392-407
221. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G. and Moussignac, R. L. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037
222. Tetali, S. D., Budamagunta, M. S., Simion, C., den Hartigh, L. J., Kálai, T., Hideg, K., Hatters, D. M., Weisgraber, K. H., Voss, J. C. and Rutledge, J. C. (2010) VLDL lipolysis products increase VLDL fluidity and convert apolipoprotein E4 into a more expanded conformation. J. Lipid Res. 51, 1273-1283